A mechanistic PK/PD model of AZD0171 (anti‐LIF) to support Phase II dose selection

• Главные авторы: Azar Shahraz (Автор), Mark Penney (Автор), Juliana Candido (Автор), Grace Opoku‐Ansah (Автор), Melanie Neubauer (Автор), Jim Eyles (Автор), Oluwaseun Ojo (Автор), Nelson Liu (Автор), Nadia M. Luheshi (Автор), Alex Phipps (Автор), Karthick Vishwanathan (Автор)
• Формат: ‌
• Опубликовано: Wiley, 2024-10-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract AZD0171 (INN: Falbikitug) is being developed as a humanized monoclonal antibody (mAb), immunoglobulin G subclass 1 (IgG1), which binds specifically to the immunosuppressive human cytokine leukemia inhibitory factor (LIF) and inhibits downstream signaling by blocking recruitment of glycoprot...